US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6479055B1
(en)
*
|
1993-06-07 |
2002-11-12 |
Trimeris, Inc. |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
|
US20070202127A1
(en)
*
|
1993-06-07 |
2007-08-30 |
Duke University |
Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
|
FR2719593B1
(fr)
*
|
1994-05-06 |
1996-05-31 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US20030198640A1
(en)
*
|
1994-11-07 |
2003-10-23 |
Human Genome Sciences, Inc. |
Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
|
WO1996018412A1
(en)
*
|
1994-12-12 |
1996-06-20 |
Beth Israel Hospital Association |
Chimeric cytokines and uses thereof
|
US6410008B1
(en)
|
1994-12-12 |
2002-06-25 |
Beth Israel Hospital Association |
Chimeric IL-10 proteins and uses thereof
|
GB9526733D0
(en)
*
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6423512B1
(en)
|
1996-07-26 |
2002-07-23 |
Novartis Ag |
Fusion polypeptides
|
US7285267B2
(en)
*
|
1997-01-14 |
2007-10-23 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptors 6α & 6β
|
US20040013664A1
(en)
*
|
1997-01-14 |
2004-01-22 |
Gentz Reiner L. |
Tumor necrosis factor receptors 6 alpha & 6 beta
|
AT406373B
(de)
*
|
1997-02-27 |
2000-04-25 |
Immuno Ag |
Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
|
AT405403B
(de)
|
1997-02-27 |
1999-08-25 |
Immuno Ag |
Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
|
CA2288306A1
(en)
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
AT408443B
(de)
*
|
1998-02-27 |
2001-11-26 |
Immuno Ag |
Verfahren zur gewinnung von gereinigtem faktor viii:c/vwf-komplex
|
US6656906B1
(en)
|
1998-05-20 |
2003-12-02 |
Trimeris, Inc. |
Hybrid polypeptides with enhanced pharmacokinetic properties
|
US6605222B1
(en)
*
|
1998-05-20 |
2003-08-12 |
Baxter Aktiengesellschaft |
Method for producing a factor VIII/von Willebrand factor complex
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
CA2330527A1
(en)
|
1998-06-15 |
1999-12-23 |
Genzyme Transgenics Corporation |
Erythropoietin analog-human serum albumin fusion
|
US6475743B1
(en)
*
|
1998-10-02 |
2002-11-05 |
Ischemia Technologies, Inc. |
Marker useful for detection and measurement of free radical damage and method
|
US7449338B2
(en)
|
1998-10-02 |
2008-11-11 |
Ischemia Technologies, Inc. |
Tests for the rapid evaluation of ischemic states and kits
|
US20050142613A1
(en)
*
|
1998-10-02 |
2005-06-30 |
David Bar-Or |
Test for the rapid evaluation of ischemic states and kits
|
US20030215359A1
(en)
*
|
1998-10-02 |
2003-11-20 |
Ischemia Technologies, Inc. |
Tests for the rapid evaluation of ischemic states and kits
|
US7070937B1
(en)
|
1998-10-02 |
2006-07-04 |
Ischemia Technologies, Inc. |
Marker useful for detection and measurement of free radical damage and method
|
US7297544B2
(en)
*
|
1998-10-02 |
2007-11-20 |
Ischemia Technologies, Inc. |
Tests for the rapid evaluation of ischemic states and kits
|
US20030190740A1
(en)
*
|
1998-10-13 |
2003-10-09 |
The University Of Georgia Research Foundation, Inc |
Stabilized bioactive peptides and methods of identification, synthesis, and use
|
GB9824632D0
(en)
*
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
DE60000665T3
(de)
*
|
1999-05-17 |
2009-10-29 |
ConjuChem Biotechnologies Inc., Montreal |
Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
|
US20040266673A1
(en)
*
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
US7601691B2
(en)
*
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US6951738B2
(en)
*
|
1999-07-16 |
2005-10-04 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptors TR13 and TR14
|
US20020048571A1
(en)
*
|
1999-07-19 |
2002-04-25 |
Jeno Gyuris |
Chimeric polypeptides of serum albumin and uses related thereto
|
US6797695B1
(en)
|
1999-10-22 |
2004-09-28 |
Kyoto University |
Human FGF-20 gene and gene expression products
|
EP2163626A1
(de)
|
1999-11-18 |
2010-03-17 |
Novartis Vaccines and Diagnostics, Inc. |
Menschliches FGF-21 Gen und Genexpressionsprodukte
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
DE60138535D1
(de)
*
|
2000-02-04 |
2009-06-10 |
Children S Hospital Res Founda |
Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
|
CA2747325A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
CA2407910C
(en)
|
2000-06-16 |
2013-03-12 |
Steven M. Ruben |
Antibodies that immunospecifically bind to blys
|
AU2001280705A1
(en)
*
|
2000-07-24 |
2002-02-05 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptors tr21 and tr22
|
AU2001286688A1
(en)
*
|
2000-08-25 |
2002-03-13 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptors 6alpha and 6beta
|
BR0116024A
(pt)
*
|
2000-12-07 |
2005-12-13 |
Lilly Co Eli |
Proteìna de fusão heteróloga e uso da mesma
|
CN1564826A
(zh)
|
2001-02-09 |
2005-01-12 |
人类基因组科学公司 |
人类g蛋白趋化因子受体(ccr5)hdgnr10
|
WO2002074806A2
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
FR2822834B1
(fr)
*
|
2001-04-02 |
2005-02-25 |
Flamel Tech Sa |
Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
|
CN1558773A
(zh)
*
|
2001-04-06 |
2004-12-29 |
巴斯德研究院 |
由与破伤风类毒素结合的霍乱弧菌o139的脂多糖的多糖部分组成的缀合疫苗
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
血管内皮増殖因子2
|
US7064189B2
(en)
|
2001-05-25 |
2006-06-20 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
US20030143191A1
(en)
*
|
2001-05-25 |
2003-07-31 |
Adam Bell |
Chemokine beta-1 fusion proteins
|
AU2002302277A1
(en)
*
|
2001-05-31 |
2002-12-09 |
Conjuchem, Inc. |
Long lasting fusion peptide inhibitors for hiv infection
|
CA2457903C
(en)
|
2001-08-24 |
2018-04-17 |
University Of Victoria Innovation And Development Corporation |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
US20030226155A1
(en)
*
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US20040023334A1
(en)
*
|
2001-08-30 |
2004-02-05 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US20070031440A1
(en)
*
|
2001-08-30 |
2007-02-08 |
Prior Christopher P |
Modified transferin-antibody fusion proteins
|
US20030228298A1
(en)
*
|
2001-09-04 |
2003-12-11 |
Mark Nesbit |
Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
|
US6797493B2
(en)
*
|
2001-10-01 |
2004-09-28 |
Lee-Hwei K. Sun |
Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
|
AU2002332041A1
(en)
*
|
2001-10-05 |
2003-04-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080194481A1
(en)
*
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
EP1463751B1
(de)
*
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
EP1463752A4
(de)
*
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
US20080167238A1
(en)
*
|
2001-12-21 |
2008-07-10 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
KR100441384B1
(ko)
*
|
2002-01-08 |
2004-07-21 |
주식회사 안지오랩 |
인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
|
WO2003062395A2
(en)
*
|
2002-01-18 |
2003-07-31 |
Bristol-Myers Squibb Company |
Predictor sets for tyrosine kinase pathways
|
US20060241027A1
(en)
*
|
2002-02-07 |
2006-10-26 |
Hans-Peter Hauser |
Hiv inhibiting proteins
|
US20050222023A1
(en)
*
|
2002-02-07 |
2005-10-06 |
Hans-Peter Hauser |
Albumin-fused kunitz domain peptides
|
ZA200406124B
(en)
*
|
2002-02-07 |
2008-09-25 |
Delta Biotechnology Ltd |
Albumin-fused kunitz domain peptides
|
EP1497445A2
(de)
*
|
2002-04-01 |
2005-01-19 |
Human Genome Sciences, Inc. |
Spezifisch an gmad bindende antikörper
|
EP1499352A4
(de)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Rekombinante anti-interleukin-9-antikörper
|
MXPA04010522A
(es)
|
2002-04-23 |
2004-12-13 |
Cargill Inc |
Polipeptidos y vias biosinteticas.
|
EP1837031B1
(de)
*
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Methoden und Kompositionen um Diabetes zu behandeln
|
FR2840614B1
(fr)
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
|
US7563882B2
(en)
*
|
2002-06-10 |
2009-07-21 |
University Of Rochester |
Polynucleotides encoding antibodies that bind to the C35 polypeptide
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
AU2003256566A1
(en)
*
|
2002-07-16 |
2004-02-02 |
Stuart Bussell |
Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
|
FR2843117B1
(fr)
*
|
2002-07-30 |
2004-10-15 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
|
CA2497338A1
(en)
|
2002-08-30 |
2004-03-18 |
Japan Science And Technology Corporation |
Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
|
CN1713920A
(zh)
*
|
2002-08-30 |
2005-12-28 |
比奥雷克西斯药物公司 |
被修饰的转铁蛋白融合蛋白
|
US20060105387A1
(en)
*
|
2002-08-30 |
2006-05-18 |
Prior Christopher P |
Transferrin fusion proteins libraries
|
US20040052777A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Mark Nesbit |
Kringle polypeptides and methods for using them to inhibit angiogenesis
|
US20040229810A1
(en)
*
|
2002-10-22 |
2004-11-18 |
Antonio Cruz |
Gastrin compositions and formulations, and methods of use and preparation
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
US20050221443A1
(en)
*
|
2003-01-06 |
2005-10-06 |
Xencor, Inc. |
Tumor necrosis factor super family agonists
|
US7553930B2
(en)
*
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
ES2398460T3
(es)
|
2003-02-06 |
2013-03-19 |
Queen's University Of Belfast |
Péptido antagonista del receptor B2 de bradiquinina proveniente de la piel de un anfibio
|
US20070060512A1
(en)
*
|
2003-03-04 |
2007-03-15 |
Homayoun Sadeghi |
Dipeptidyl-peptidase protected protein
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
US20050079546A1
(en)
*
|
2003-05-01 |
2005-04-14 |
Dasa Lipovsek |
Serum albumin scaffold-based proteins and uses thereof
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20080039379A1
(en)
*
|
2003-05-27 |
2008-02-14 |
Waratah Pharmaceuticals, Inc. |
Compositions Comprising Gastrin Compounds and Their Use in Diabetes
|
FR2855521B1
(fr)
*
|
2003-05-28 |
2005-08-05 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
|
CA2532250A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases
|
WO2005012346A1
(en)
*
|
2003-07-25 |
2005-02-10 |
Conjuchem, Inc. |
Long lasting insulin derivatives and methods thereof
|
US20060205037A1
(en)
*
|
2003-08-28 |
2006-09-14 |
Homayoun Sadeghi |
Modified transferrin fusion proteins
|
EP1663278A4
(de)
*
|
2003-08-28 |
2009-07-29 |
Biorexis Pharmaceutical Corp |
Epo mimetika-peptide und fusionsproteine
|
FR2860516B1
(fr)
*
|
2003-10-03 |
2006-01-13 |
Flamel Tech Sa |
Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
|
WO2005035564A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
EP2256134B1
(de)
|
2003-11-13 |
2014-01-08 |
Hanmi Science Co., Ltd. |
IgG-Fc-Fragment für einen Arzneimittelträger und Verfahren zu dessen Herstellung
|
FR2862536B1
(fr)
*
|
2003-11-21 |
2007-11-23 |
Flamel Tech Sa |
Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
|
FR2862535B1
(fr)
*
|
2003-11-21 |
2007-11-23 |
Flamel Tech Sa |
Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
|
EP1708751B1
(de)
*
|
2003-12-04 |
2011-09-28 |
Vaccinex, Inc. |
Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
JP2007518423A
(ja)
*
|
2004-01-23 |
2007-07-12 |
イントロン、インコーポレイテッド |
スプライセオソーム仲介型rnaトランススプライシングを使用するアポa−1及びその変異体の発現
|
PL1729795T3
(pl)
*
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
US7973139B2
(en)
*
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
EP1750754A4
(de)
*
|
2004-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
Menschliche glp-1-mimetikörper; zusammensetzungen; verfahren und anwendungen
|
JP2008505059A
(ja)
*
|
2004-05-06 |
2008-02-21 |
コンジュシェム バイオテクノロジーズ インコーポレイティド |
特異的ウイルス標的用化合物
|
EP2287310B1
(de)
|
2004-07-22 |
2015-05-06 |
Five Prime Therapeutics, Inc. |
Zusammensetzungen und Verfahren zur Verwendung von MGD-CSF zur Krankheitsbehandlung
|
EP1786831A4
(de)
|
2004-07-30 |
2008-01-23 |
Cargill Inc |
Alanin-2,3-aminomutasen
|
JP2008512097A
(ja)
*
|
2004-09-07 |
2008-04-24 |
アーケミックス コーポレイション |
アプタマー医薬品化学
|
US7566701B2
(en)
*
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
EP1789096A4
(de)
|
2004-09-07 |
2009-07-08 |
Archemix Corp |
Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
AU2005286662B2
(en)
|
2004-09-23 |
2011-10-06 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
AU2005326784B2
(en)
*
|
2004-10-08 |
2012-03-15 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
CA2583254A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Intronn, Inc. |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
JP5058822B2
(ja)
|
2005-01-25 |
2012-10-24 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
心臓の状態を処置するための組成物および方法
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
US7723472B2
(en)
*
|
2005-02-28 |
2010-05-25 |
The Regents Of The University Of California |
Extracellular matrix binding chimeric proteins and methods of use thereof
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
UA95446C2
(ru)
*
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Мутаци в генах oas1
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
EP1891111A1
(de)
|
2005-05-06 |
2008-02-27 |
ZymoGenetics, Inc. |
Monoklonale il-31-antikörper und anwendungsverfahren
|
US20060292609A1
(en)
*
|
2005-05-19 |
2006-12-28 |
Schering Aktiengesellschaft |
Interferon-beta gene therapy using an improved, regulated expression system
|
US20080076729A1
(en)
*
|
2005-05-19 |
2008-03-27 |
Schering Aktiengesellachaft |
Interferon-beta gene therapy using an improved, regulated expression system
|
CA2608764A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Schering Ag |
Treatment of disease using an improved regulated expression system
|
US20070179113A1
(en)
*
|
2005-05-19 |
2007-08-02 |
Schering Aktiengesellachaft |
GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
|
US20090275481A1
(en)
*
|
2005-06-17 |
2009-11-05 |
Pfizer, Inc. |
Anchored Transferrin Fusion Protein Libraries
|
ES2336832T3
(es)
|
2005-07-22 |
2010-04-16 |
Five Prime Therapeutics, Inc. |
Composiciones y procedimientos para tratar enfermedades con proteinas de fusion de fgfr.
|
CA2618681C
(en)
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
EP3037544A1
(de)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Verfahren und zusammensetzung zur verwendung bei der behandlung von systemisch lupus erythematosus patienten mit autoantikörper-positiven leiden
|
CA2562249A1
(en)
*
|
2005-10-20 |
2007-04-20 |
University Of Ottawa Heart Institute |
Anf analogue
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
EP3058972A1
(de)
|
2005-11-17 |
2016-08-24 |
Zogenix, Inc. |
Abgabe von viskosen formulierungen durch nadellose injektion
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
CA2634034A1
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
CN101384623B
(zh)
*
|
2005-12-22 |
2013-07-24 |
常山凯捷健生物药物研发(河北)有限公司 |
白蛋白与治疗剂的预成型偶联物的制备方法
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
EP1816201A1
(de)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
CA2646329C
(en)
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
AU2007258609B2
(en)
*
|
2006-06-07 |
2013-01-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
GB0611405D0
(en)
*
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
EP2046826B1
(de)
|
2006-07-24 |
2011-09-14 |
Biorexis Pharmaceutical Corporation |
Exendin-fusionsproteine
|
TW200817438A
(en)
*
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
BRPI0715660B8
(pt)
|
2006-09-01 |
2021-05-25 |
Zymogenetics Inc |
anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
|
EP2354254A1
(de)
|
2006-09-06 |
2011-08-10 |
Ortho-McNeil Pharmaceutical, Inc. |
Biomarker zur Überprüfung der Reaktion auf eine C-Met-Behandlung
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
EP2114437A2
(de)
*
|
2006-10-16 |
2009-11-11 |
ConjuChem Biotechnologies Inc. |
Modifizierte peptide mit corticotropinfreisetzungsfaktor und verwendungen davon
|
US8268347B1
(en)
|
2006-10-24 |
2012-09-18 |
Aradigm Corporation |
Dual action, inhaled formulations providing both an immediate and sustained release profile
|
WO2008052043A2
(en)
*
|
2006-10-24 |
2008-05-02 |
Cogenesys, Inc. |
Opioid receptor agonist fusion proteins
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2008140472A2
(en)
*
|
2006-10-27 |
2008-11-20 |
The Regents Of The University Of California |
Functionalized molecules comprising an autosilification moiety and methods of making and using same
|
AU2007351813B2
(en)
|
2006-10-31 |
2013-10-10 |
East Carolina University |
Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
|
WO2008056961A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Boryung Pharmaceutical Co., Ltd |
A novel fusion protein, cell lines expressing the same and preparation method thereof
|
EP2120998B1
(de)
|
2006-11-28 |
2013-08-07 |
HanAll Biopharma Co., Ltd. |
Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
|
EP3231440A1
(de)
*
|
2006-12-22 |
2017-10-18 |
CSL Behring GmbH |
Veränderte koagulationsfaktoren mit verlängerter in-vivo-halbwertzeit
|
US20090099074A1
(en)
*
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
US20090088378A1
(en)
*
|
2007-01-12 |
2009-04-02 |
Omar Quraishi |
Long lasting inhibitors of viral infection
|
EP2450371B1
(de)
|
2007-01-30 |
2015-04-29 |
Epivax, Inc. |
Regulatorische t-zellen-epitope sowie zusammensetzungen damit und anwendungen davon
|
HUP0700203A2
(en)
*
|
2007-03-08 |
2008-12-29 |
Univ Szegedi |
Sustained release, core-shell structure precipitated citokine bionanocomposit, a process for producing the same and use thereof
|
EP2136832B1
(de)
|
2007-03-26 |
2015-09-02 |
General Regeneratives Limited |
Verfahren zur förderung des schutzes und der regeneration von knochenmark mit cxcl9 und anti-cxcl9-antikörpern
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
WO2008136790A1
(en)
|
2007-05-02 |
2008-11-13 |
Merial Limited |
Dna plasmids having improved expression and stability
|
JP2010525821A
(ja)
|
2007-05-02 |
2010-07-29 |
アンブルックス,インコーポレイテッド |
修飾IFNβポリペプチドおよびこれらの使用
|
EP2068925A4
(de)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
Anti-icos-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
ES2558689T3
(es)
|
2007-05-14 |
2016-02-08 |
Medimmune, Llc |
Métodos para reducir los niveles de eosinófilos
|
AU2008254767A1
(en)
*
|
2007-05-16 |
2008-11-27 |
Conjuchem Biotechnologies Inc. |
Cysteic acid derivatives of anti-viral peptides
|
US8420779B2
(en)
*
|
2007-05-22 |
2013-04-16 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008150495A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Archemix Corp. |
Vwf aptamer formulations and methods for use
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
WO2008157824A2
(en)
*
|
2007-06-21 |
2008-12-24 |
Conjuchem Biotechnologies Inc. |
Thrombopoietin peptide conjugates
|
CL2008002054A1
(es)
*
|
2007-07-17 |
2009-05-29 |
Hoffmann La Roche |
Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
|
CL2008002053A1
(es)
*
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
|
CL2008002092A1
(es)
*
|
2007-07-20 |
2009-05-29 |
Hoffmann La Roche |
Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
|
WO2009012600A1
(en)
|
2007-07-26 |
2009-01-29 |
Novagen Holding Corporation |
Fusion proteins
|
WO2009023549A2
(en)
*
|
2007-08-09 |
2009-02-19 |
University Of Rochester |
Vaccine against botulism
|
AU2008287340A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
NZ583605A
(en)
|
2007-08-29 |
2012-10-26 |
Sanofi Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
US8273561B2
(en)
*
|
2007-10-05 |
2012-09-25 |
Nuron Biotech, Inc. |
High pressure treatment of aggregated interferons
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
DK2217265T3
(en)
|
2007-11-20 |
2017-07-03 |
Ambrx Inc |
Modified insulin polypeptides and their use
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
LT2796466T
(lt)
|
2007-12-07 |
2018-02-26 |
Zymogenetics, Inc. |
Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
EP2245064B1
(de)
|
2007-12-21 |
2014-07-23 |
Medimmune Limited |
BINDUNGSELEMENTE FÜR INTERLEUKIN-4-REZEPTOR ALPHA (IL-4Ralpha)
|
AU2008341050B2
(en)
|
2007-12-26 |
2013-10-24 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
US20110020368A1
(en)
|
2008-03-25 |
2011-01-27 |
Nancy Hynes |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
AU2009241847B2
(en)
|
2008-04-28 |
2014-07-10 |
Zogenix, Inc. |
Novel formulations for treatment of migraine
|
EP2383292A1
(de)
|
2008-05-02 |
2011-11-02 |
Novartis AG |
Verbesserte Bindemoleküle auf Fibronectin-Basis und ihre Verwendung
|
US8575104B2
(en)
|
2008-06-24 |
2013-11-05 |
Csl Behring Gmbh |
Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
|
US20100048488A1
(en)
*
|
2008-08-01 |
2010-02-25 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
DK2328616T3
(en)
|
2008-08-05 |
2015-07-20 |
Novartis Ag |
Compositions and Methods for Antibodies to Complement Protein C5
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
KR20110093775A
(ko)
*
|
2008-11-03 |
2011-08-18 |
바이엘 헬스케어 엘엘씨 |
혈우병 치료 방법
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
CN102282168A
(zh)
*
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
WO2010083439A2
(en)
|
2009-01-16 |
2010-07-22 |
Teva Biopharmaceuticals Usa, Inc. |
Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
PT2393828T
(pt)
|
2009-02-03 |
2017-01-18 |
Amunix Operating Inc |
Polipéptidos recombinantes estendidos e composições que compreendem os mesmos
|
SG2014012918A
(en)
|
2009-02-11 |
2014-04-28 |
Novozymes Biopharma Dk As |
Albumin variants and conjugates
|
ES2712732T3
(es)
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
EP2405920A1
(de)
|
2009-03-06 |
2012-01-18 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue therapie gegen angstzustände
|
EP2413958A4
(de)
|
2009-03-31 |
2014-04-02 |
Univ East Carolina |
Cytokine und neuroantigene zur behandlung von immunerkrankungen
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
EP2423233B1
(de)
|
2009-04-22 |
2015-03-11 |
Alteogen, Inc |
Durch in-vivo-freisetzung stabilisiertes fusionsprotein mit erhöhter in-vivo-halbwertzeit sowie verfahren zur erhöhung der in-vivo-halbwertzeit damit
|
EP2427486B1
(de)
|
2009-05-07 |
2015-02-25 |
Novozymes Biopharma DK A/S |
Verfahren zur Aufreinigung von Albumin
|
US11512326B2
(en)
|
2009-05-26 |
2022-11-29 |
University Of Florida Research Foundation, Incorporated |
Small angiotensin peptide expression system in mammalian cells
|
WO2011005939A2
(en)
|
2009-07-09 |
2011-01-13 |
Mayo Foundation For Medical Education And Research |
Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
|
US8945895B2
(en)
*
|
2009-07-31 |
2015-02-03 |
Baxter International Inc. |
Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
|
EP2464661B1
(de)
|
2009-08-13 |
2018-01-17 |
The Johns Hopkins University |
Verfahren zur modulierung der immunfunktion mittles anti-b7-h7cr antikörper
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
US8451450B2
(en)
*
|
2009-09-14 |
2013-05-28 |
Bio-Rad Laboratories, Inc. |
Near real time optical phase conjugation
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
NZ598465A
(en)
|
2009-10-30 |
2013-10-25 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
GB2488077A
(en)
|
2009-10-30 |
2012-08-15 |
Novozymes Biopharma Dk As |
Albumin variants
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
CN102164949B
(zh)
|
2009-11-19 |
2013-10-23 |
浙江大学 |
新型重组融合蛋白
|
BR112012012526A2
(pt)
*
|
2009-11-24 |
2016-05-03 |
Syngenta Participations Ag |
misturas estáveis e métodos relacionados
|
MX354143B
(es)
|
2009-12-02 |
2018-02-14 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
|
PL3326643T3
(pl)
|
2009-12-06 |
2021-10-25 |
Bioverativ Therapeutics Inc. |
Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
|
TWI409082B
(zh)
|
2010-01-19 |
2013-09-21 |
Hanmi Science Co Ltd |
用於長效型粒細胞集落刺激因子(g-csf)共軛物之液態劑型
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
EP2542578A1
(de)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c und hirnkrebs
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
EP4234698A3
(de)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
|
EP2580239A1
(de)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
|
JP2013529627A
(ja)
|
2010-06-24 |
2013-07-22 |
パンメド リミテッド |
ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するc型肝炎ウイルス関連疾患の処置
|
EP2585098B1
(de)
|
2010-06-28 |
2014-08-27 |
Five Prime Therapeutics, Inc. |
Extrazelluläre fzd8-domänen und fusionsmoleküle aus extrazellulären fzd8-domänen für verwendung in der behandlung von obesität und obesität-bedingten erkrankungen
|
NZ605348A
(en)
|
2010-07-09 |
2015-01-30 |
Biogen Idec Hemophilia Inc |
Factor ix polypeptides and methods of use thereof
|
NZ605400A
(en)
|
2010-07-09 |
2015-05-29 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
BR112013004012B1
(pt)
|
2010-08-20 |
2021-03-23 |
Novartis Ag |
Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
|
EP2608807A1
(de)
|
2010-08-27 |
2013-07-03 |
Stem Centrx, Inc. |
Notumproteinmodulatoren und verwendungsverfahren
|
EP2611464B1
(de)
|
2010-09-03 |
2018-04-25 |
AbbVie Stemcentrx LLC |
Neue modulatoren und deren verwendung
|
EP2614080A1
(de)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphoryliertes twist1 und metastasen
|
WO2012035037A1
(en)
|
2010-09-14 |
2012-03-22 |
F. Hoffmann-La Roche Ag |
Method for purifying pegylated erythropoietin
|
DK2635607T3
(da)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
EP2640738A1
(de)
|
2010-11-15 |
2013-09-25 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Antimykotische wirkstoffe
|
AU2011329127B2
(en)
|
2010-11-15 |
2015-09-03 |
Five Prime Therapeutics, Inc. |
FGFR1 extracellular domain combination therapies
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
KR20190112175A
(ko)
|
2010-12-01 |
2019-10-02 |
앨더바이오 홀딩스 엘엘씨 |
항―ngf 조성물 및 그의 용도
|
SG190990A1
(en)
|
2010-12-08 |
2013-07-31 |
Stem Centrx Inc |
Novel modulators and methods of use
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
AU2012205301B2
(en)
|
2011-01-14 |
2017-01-05 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
WO2012097238A2
(en)
|
2011-01-14 |
2012-07-19 |
Five Prime Therapeutics, Inc. |
Il-27 antagonists for treating inflammatory diseases
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
CA2836800A1
(en)
|
2011-05-20 |
2012-11-29 |
Alderbio Holdings Llc |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
US9855332B2
(en)
|
2011-05-20 |
2018-01-02 |
Alderbio Holdings Llc |
Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
|
CN107602700B
(zh)
|
2011-05-20 |
2021-12-17 |
H.伦德贝克公司 |
抗cgrp组合物及其用途
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
SI2717898T1
(sl)
|
2011-06-10 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Spojine prokoagulantov in metode za njihovo uporabo
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
AR087020A1
(es)
|
2011-07-01 |
2014-02-05 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos
|
CN103649111B
(zh)
|
2011-07-05 |
2018-03-13 |
阿尔布梅迪克斯医疗公司 |
白蛋白制剂和用途
|
WO2013007563A1
(en)
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
DK3513804T3
(da)
|
2011-07-08 |
2022-06-20 |
Bioverativ Therapeutics Inc |
Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf
|
EP2737311B1
(de)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Tests zur überwachung von blutungsstörungen
|
EP2751136B1
(de)
|
2011-08-30 |
2017-10-18 |
Mayo Foundation For Medical Education And Research |
Natriuretische polypeptide
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
KR102434073B1
(ko)
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
CA2853951A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
EP2773667A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
WO2013067355A1
(en)
|
2011-11-04 |
2013-05-10 |
Novartis Ag |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
CN109897103A
(zh)
|
2011-11-04 |
2019-06-18 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
EP2776838A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Frühe diagnose neurodegenerativer erkrankungen
|
WO2013075066A2
(en)
|
2011-11-18 |
2013-05-23 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
US9493515B2
(en)
|
2011-11-29 |
2016-11-15 |
Proclara Biosciences, Inc. |
Bacteriophage gene 3 protein compositions and use as amyloid binding agents
|
JP2015500829A
(ja)
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)のドメインiiに対するher3の抗体
|
WO2013084147A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
ES2728278T3
(es)
|
2011-12-21 |
2019-10-23 |
Novartis Ag |
Composiciones que comprenden anticuerpos dirigidos al factor P y C5
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
US9611305B2
(en)
|
2012-01-06 |
2017-04-04 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
US9944691B2
(en)
|
2012-03-16 |
2018-04-17 |
Albumedix A/S |
Albumin variants
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
EP2830646B1
(de)
|
2012-03-27 |
2018-03-07 |
NGM Biopharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
US10064951B2
(en)
|
2012-03-30 |
2018-09-04 |
Hanmi Science Co., Ltd. |
Liquid formulation of highly concentrated long-acting human growth hormone conjugate
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
CA2872540A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
KR20220051197A
(ko)
|
2012-05-17 |
2022-04-26 |
익스텐드 바이오사이언시즈, 인크. |
개선된 약물 전달용 캐리어
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
EP2854834A4
(de)
|
2012-05-30 |
2016-05-18 |
Biostrategies LC |
Pflanzenlektine als träger entsprechender wirkstoffe in tierischen und menschlichen zellen
|
EP2857417B1
(de)
|
2012-06-05 |
2018-02-14 |
CJ Healthcare Corporation |
Hochglykosyliertes hgh-protein und herstellungsverfahren dafür
|
EP2866831A1
(de)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
EP2870242A1
(de)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
US20150202287A1
(en)
|
2012-08-30 |
2015-07-23 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
EP3738605A1
(de)
|
2012-09-10 |
2020-11-18 |
Xencor, Inc. |
Verfahren zur behandlung von neurologischen erkrankungen
|
EP2900328A4
(de)
|
2012-09-25 |
2016-05-11 |
Biogen Ma Inc |
Verfahren zur verwendung von fix-polypeptiden
|
DK2906235T3
(en)
|
2012-10-02 |
2017-09-25 |
Proclara Biosciences Inc |
USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
|
EP3446700A1
(de)
|
2012-10-30 |
2019-02-27 |
Bioverativ Therapeutics Inc. |
Verfahren zur verwendung von fviii-polypeptid
|
BR112015010318A2
(pt)
|
2012-11-08 |
2017-08-22 |
Albumedix As |
Variantes de albumina
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
EP3851454A1
(de)
|
2012-12-05 |
2021-07-21 |
Novartis AG |
Zusammensetzungen und verfahren für gegen epo gerichtete antikörper
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
JP6272907B2
(ja)
|
2013-01-30 |
2018-01-31 |
エヌジーエム バイオファーマシューティカルズ インコーポレイテッド |
代謝障害の処置における組成物及び使用方法
|
EP2954048A1
(de)
|
2013-02-08 |
2015-12-16 |
Friedrich Miescher Institute for Biomedical Research |
Neuartige verfahren zur gezielten einführung von viren in zellen
|
WO2014127120A1
(en)
|
2013-02-15 |
2014-08-21 |
Mayo Foundation For Medical Education And Research |
Insulin secreting polypeptides
|
RS60026B1
(sr)
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
USRE48805E1
(en)
*
|
2013-03-06 |
2021-11-02 |
Vision Global Holdings Ltd. |
Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
|
US9255262B2
(en)
*
|
2013-03-06 |
2016-02-09 |
Vision Global Holdings Ltd. |
Albumin-binding arginine deminase and the use thereof
|
CA2940513C
(en)
|
2013-03-11 |
2023-08-15 |
University Of Florida Research Foundation, Inc. |
Delivery of card protein as therapy for ocular inflammation
|
EP3611189A1
(de)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antikörper gegen notch 3
|
WO2014144795A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Factor viii polypeptide formulations
|
SG10201913874TA
(en)
|
2013-03-15 |
2020-03-30 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
WO2014147489A2
(en)
|
2013-03-15 |
2014-09-25 |
Teva Pharmaceutical Industries Ltd. |
Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
|
EP3473272A1
(de)
|
2013-03-29 |
2019-04-24 |
Alexion Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur erhöhung der serumhalbwertzeit eines therapeutischen, gegen komplement c5 gerichteten mittels
|
JP2016519108A
(ja)
|
2013-04-18 |
2016-06-30 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−10を疾病及び疾患の治療に用いる方法
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
SG11201508878WA
(en)
|
2013-05-01 |
2015-11-27 |
Five Prime Therapeutics Inc |
Methods of treating cancer
|
EP2999799A4
(de)
|
2013-05-23 |
2016-12-28 |
Five Prime Therapeutics Inc |
Verfahren zur behandlung von karzinomen
|
CN105473153A
(zh)
|
2013-05-28 |
2016-04-06 |
神经噬菌体制药股份有限公司 |
包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽
|
JP2016528879A
(ja)
|
2013-06-17 |
2016-09-23 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
タンパク質の同一性および安定性を評価する方法
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
TWI712419B
(zh)
|
2013-07-03 |
2020-12-11 |
美商艾爾德生物製藥股份有限公司 |
使用抗cgrp抗體之葡萄糖代謝的調節
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
CN105792836A
(zh)
|
2013-08-28 |
2016-07-20 |
施特姆森特克斯股份有限公司 |
新型sez6调节剂以及应用方法
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
JP6509867B2
(ja)
|
2013-08-30 |
2019-05-08 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためにインターロイキン−10を使用する方法
|
WO2015066550A1
(en)
*
|
2013-10-31 |
2015-05-07 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
RU2016122957A
(ru)
|
2013-11-11 |
2017-12-19 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
EP4332839A2
(de)
|
2013-12-06 |
2024-03-06 |
Bioverativ Therapeutics Inc. |
Pharmakokinetische werkzeuge für populationen und verwendungen davon
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
EA038573B1
(ru)
|
2014-03-24 |
2021-09-16 |
Биовератив Терапьютикс Инк. |
Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения
|
CN106536556B
(zh)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
结合lgr5的人源化抗体
|
WO2015168207A1
(en)
|
2014-04-29 |
2015-11-05 |
Mayo Foundation For Medical Education And Research |
Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
|
MX2016014306A
(es)
|
2014-05-02 |
2017-06-12 |
Cerenis Therapeutics Holding Sa |
Marcadores para terapia con lipoproteinas de alta densidad (hdl).
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
DK3173420T3
(da)
*
|
2014-07-23 |
2021-10-18 |
Nat Ct Nanoscience & Technology China |
Polypeptid og polypeptidkompleks til undertrykkelse af tumormetastase og behandling af leukæmi samt fremgangsmåde til fremstilling deraf og anvendelse deraf
|
PE20170771A1
(es)
|
2014-07-30 |
2017-07-04 |
Ngm Biopharmaceuticals Inc |
Composiciones y metodos de uso para tratar trastornos metabolicos
|
EP3194437B1
(de)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Antikörper gegen angiopoietinähnliches protein 4 und deren verwendung
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
US20170224777A1
(en)
|
2014-08-12 |
2017-08-10 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
|
EP3197557A1
(de)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats und brustrkrebs
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CA2909044A1
(en)
*
|
2014-10-10 |
2016-04-10 |
Queen's University At Kingston |
Rhomboid proteins and uses thereof
|
KR20170068553A
(ko)
|
2014-10-14 |
2017-06-19 |
아르모 바이오사이언시스 인코포레이티드 |
인터류킨-15 조성물 및 이의 용도
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
JP6675394B2
(ja)
|
2014-10-22 |
2020-04-01 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害の治療のためにインターロイキン−10を使用する方法
|
US9585934B2
(en)
|
2014-10-22 |
2017-03-07 |
Extend Biosciences, Inc. |
Therapeutic vitamin D conjugates
|
EP3209681A4
(de)
|
2014-10-23 |
2018-10-31 |
NGM Biopharmaceuticals, Inc. |
Pharmazeutische zusammensetzungen mit peptidvarianten und verfahren zur verwendung davon
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
EP3701969A1
(de)
|
2014-10-31 |
2020-09-02 |
NGM Biopharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur verwendung zur behandlung von stoffwechselerkrankungen
|
MX2017006663A
(es)
|
2014-11-19 |
2017-08-21 |
Axon Neuroscience Se |
Anticuerpos tau humanizados en enfermedad de alzheimer.
|
AU2015358504A1
(en)
|
2014-12-03 |
2017-06-29 |
Proclara Biosciences, Inc. |
Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
|
EP3227319B1
(de)
*
|
2014-12-04 |
2019-11-27 |
Novartis AG |
Verfahren und zusammensetzungen mit polypeptiden der klotho-variante
|
EP3835319A1
(de)
|
2014-12-19 |
2021-06-16 |
Alder Biopharmaceuticals, Inc. |
Humanisierte anti-acth-antikörper und verwendungen davon
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3842451A1
(de)
|
2015-03-12 |
2021-06-30 |
MedImmune, LLC |
Verfahren zur aufreinigung von albuminfusionsproteinen
|
CA2984947A1
(en)
|
2015-05-19 |
2016-11-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
JP7121496B2
(ja)
|
2015-05-28 |
2022-08-18 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
癌治療で使用するためのペグ化インターロイキン-10
|
WO2016196211A1
(en)
|
2015-05-29 |
2016-12-08 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
PE20180041A1
(es)
|
2015-06-05 |
2018-01-09 |
Novartis Ag |
Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
|
CA2988588A1
(en)
|
2015-06-12 |
2016-12-15 |
Georgia State University Research Foundation, Inc. |
Compositions and methods for treating opioid tolerance
|
AU2016279804B2
(en)
|
2015-06-15 |
2019-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating aging-associated conditions
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
EP3331914A1
(de)
|
2015-08-03 |
2018-06-13 |
Novartis AG |
Verfahren zur behandlung von fgf21-vermittelten erkrankungen
|
EP4137158A1
(de)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Gegen moleküle gerichtete antigenbindende konstrukte
|
CA2995838A1
(en)
|
2015-08-19 |
2017-02-23 |
Rutgers, The State University Of New Jersey |
Novel methods of generating antibodies
|
JP7007261B2
(ja)
|
2015-08-20 |
2022-01-24 |
アルブミディクス リミティド |
アルブミン変異体及びコンジュゲート
|
CN108025040A
(zh)
|
2015-08-25 |
2018-05-11 |
阿尔莫生物科技股份有限公司 |
使用白介素-10治疗疾病和病症的方法
|
JP6886920B2
(ja)
|
2015-09-08 |
2021-06-16 |
Jcrファーマ株式会社 |
新規なヒト血清アルブミン変異体
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
DK3347377T3
(da)
|
2015-09-09 |
2021-05-10 |
Novartis Ag |
Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
|
WO2017058923A1
(en)
|
2015-09-28 |
2017-04-06 |
East Carolina University |
Aluminum based adjuvants for tolerogenic vaccination
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
EP3888672A1
(de)
|
2015-11-09 |
2021-10-06 |
NGM Biopharmaceuticals, Inc. |
Verfahren zur behandlung von gallensäurebedingten erkrankungen
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
CN116003593A
(zh)
|
2016-01-11 |
2023-04-25 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
JP2017165713A
(ja)
|
2016-03-14 |
2017-09-21 |
Jcrファーマ株式会社 |
血清アルブミン−20k成長ホルモン融合タンパク質
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
KR102370762B1
(ko)
|
2016-03-31 |
2022-03-04 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
결합 단백질 및 이의 사용 방법
|
CA3020990A1
(en)
|
2016-04-15 |
2017-10-19 |
Alder Biopharmaceuticals, Inc. |
Humanized anti-pacap antibodies and uses thereof
|
CN115975044A
(zh)
|
2016-04-25 |
2023-04-18 |
戊瑞治疗有限公司 |
用于治疗病理性肌肉损失和虚弱的nope
|
WO2017189432A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
AU2017267047B2
(en)
*
|
2016-05-20 |
2023-11-09 |
Octapharma Ag |
Glycosylated VWF fusion proteins with improved pharmacokinetics
|
WO2017216724A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
CA3027143A1
(en)
|
2016-07-15 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Method for purifying pegylated erythropoietin
|
WO2018053216A1
(en)
|
2016-09-15 |
2018-03-22 |
Mayo Foundation For Medical Education And Research |
Methods and materials for using butyrylcholinesterases to treat cancer
|
EP3538131A4
(de)
|
2016-11-09 |
2020-07-01 |
Mayo Foundation for Medical Education and Research |
Manp-analoga
|
EP3558370A2
(de)
|
2016-12-23 |
2019-10-30 |
Novartis AG |
Behandlungsverfahren mitantikörpern gegen faktor-xi/xia
|
IL267538B1
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
MX2019009498A
(es)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Anticuerpos mimeticos de fgf21 y usos de los mismos.
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
CN110869386A
(zh)
*
|
2017-02-10 |
2020-03-06 |
维维巴巴公司 |
重组神经生长因子的组合物和方法
|
US20200131225A1
(en)
*
|
2017-04-20 |
2020-04-30 |
Novo Nordisk A/S |
Methods of purification of albumin fusion proteins
|
JP2020517271A
(ja)
|
2017-04-22 |
2020-06-18 |
イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. |
改良lamp構築物
|
JP7222915B2
(ja)
|
2017-05-02 |
2023-02-15 |
イミュノミック セラピューティックス, インコーポレイテッド |
癌抗原を含む改善されたlamp構築物
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
EP3684811A2
(de)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
|
US20200172933A1
(en)
|
2017-08-18 |
2020-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Novel methods for the targeted introduction of viruses into cells and tissues
|
CA3073537A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
US20200353050A1
(en)
|
2017-11-10 |
2020-11-12 |
Armo Biosciences, Inc. |
Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
|
JP7165193B2
(ja)
|
2017-11-27 |
2022-11-02 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ヒト組織因子を標的とするヒト化抗体
|
WO2019154985A1
(en)
|
2018-02-12 |
2019-08-15 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment using cytokine encoding rna
|
EP3774877A1
(de)
*
|
2018-03-28 |
2021-02-17 |
Bioxodes |
Antikoagulierende fusionsproteine und verwendungen davon
|
WO2019186344A1
(en)
|
2018-03-28 |
2019-10-03 |
Institut Pasteur De Tunis |
Anti-cancer and disintegrin scorpion venoms
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
EP3802611A2
(de)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Bindungsmoleküle gegen bcma und deren verwendungen
|
US20210347842A1
(en)
|
2018-06-19 |
2021-11-11 |
Eli Lilly And Company |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
AU2019311233A1
(en)
|
2018-07-24 |
2021-01-21 |
BioNTech SE |
IL2 agonists
|
CN110818793A
(zh)
*
|
2018-08-14 |
2020-02-21 |
中山康方生物医药有限公司 |
抗IL-1β的抗体、其药物组合物及其用途
|
EP3856763A1
(de)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Kollagenlokalisierte immunmodulatorische moleküle und verfahren dafür
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020109978A1
(en)
|
2018-11-26 |
2020-06-04 |
Novartis Ag |
Lpl-gpihbp1 fusion polypeptides
|
KR20210113261A
(ko)
|
2019-01-04 |
2021-09-15 |
리졸브 테라퓨틱스, 엘엘씨 |
뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
|
EP3914289A1
(de)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Dosierungsschema einer kombinationsimmunotherapie für immunprüfpunktblockade
|
AU2020218615A1
(en)
|
2019-02-08 |
2021-09-30 |
Biontech Cell & Gene Therapies Gmbh |
Treatment involving car-engineered T cells and cytokines
|
AU2020242254A1
(en)
|
2019-03-18 |
2020-09-24 |
Biontech Cell & Gene Therapies Gmbh |
Lnterleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
WO2020200481A1
(en)
|
2019-04-05 |
2020-10-08 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment involving interleukin-2 (il2) and interferon (ifn)
|
EP3972998A1
(de)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19-bindende moleküle und verwendungen davon
|
EP3972993A1
(de)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variante cd58-domänen und deren verwendungen
|
JP2022532928A
(ja)
|
2019-05-24 |
2022-07-20 |
サノフイ |
全身性硬化症を治療するための方法
|
TW202115105A
(zh)
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Rna製藥有限公司 |
Il2激動劑
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
WO2021058091A1
(en)
|
2019-09-24 |
2021-04-01 |
Biontech Rna Pharmaceuticals Gmbh |
Treatment involving therapeutic antibody and interleukin-2 (il2)
|
CN114641306A
(zh)
|
2019-10-18 |
2022-06-17 |
免疫治疗有限公司 |
包含癌抗原的改良lamp构建物
|
EP4069200A1
(de)
|
2019-12-04 |
2022-10-12 |
Albumedix Ltd |
Verfahren und damit hergestellte zusammensetzungen
|
WO2021129927A1
(en)
|
2019-12-23 |
2021-07-01 |
Biontech Cell & Gene Therapies Gmbh |
Treatment with immune effector cells engineered to express an antigen receptor
|
EP4081241A1
(de)
*
|
2019-12-24 |
2022-11-02 |
Juvena Therapeutics, Inc. |
Regenerative polypeptide und verwendungen dafür
|
WO2021129945A1
(en)
|
2019-12-27 |
2021-07-01 |
Biontech Cell & Gene Therapies Gmbh |
In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
|
US20230076768A1
(en)
|
2020-01-14 |
2023-03-09 |
Synthekine, Inc. |
IL2 Orthologs and Methods of Use
|
US20230405046A1
(en)
|
2020-03-16 |
2023-12-21 |
Biontech Cell & Gene Therapies Gmbh |
Antigen-specific t cell receptors and t cell epitopes
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
WO2021197589A1
(en)
|
2020-03-31 |
2021-10-07 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination
|
SG10202003296VA
(en)
|
2020-04-06 |
2021-11-29 |
H Lundbeck As |
Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
AU2021320233A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
IL10Ra binding molecules and methods of use
|
EP4192877A1
(de)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Synthetische il2rb/il2rg-zytokine
|
EP4192495A1
(de)
|
2020-08-07 |
2023-06-14 |
Bristol-Myers Squibb Company |
Fgf21 in kombination mit ccr2/5-antagonisten zur behandlung von fibrose
|
EP4208197A1
(de)
|
2020-09-04 |
2023-07-12 |
Rutgers, The State University of New Jersey |
Sars-cov-2-impfstoffe und -antikörper
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
EP4240491A1
(de)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19-bindende moleküle und verwendungen davon
|
US20240123031A1
(en)
|
2020-11-25 |
2024-04-18 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
EP4294834A2
(de)
|
2021-02-19 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Einzeldomänenantikörper zur neutralisierung von sars-cov-2
|
JP2024514364A
(ja)
|
2021-04-12 |
2024-04-01 |
ビオンテック・ソシエタス・エウロパエア |
緩衝物質を含むrna組成物ならびにその製造、保存および使用のための方法
|
WO2022223617A1
(en)
|
2021-04-20 |
2022-10-27 |
BioNTech SE |
Virus vaccine
|
AU2022333323A1
(en)
|
2021-08-27 |
2024-02-29 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
WO2023066496A1
(en)
|
2021-10-21 |
2023-04-27 |
BioNTech SE |
Coronavirus vaccine
|
EP4238577A3
(de)
|
2021-10-22 |
2023-12-06 |
BioNTech SE |
Zusammensetzungen zur verabreichung verschiedener dosen von rna
|
WO2023083434A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
WO2023126053A1
(en)
|
2021-12-28 |
2023-07-06 |
BioNTech SE |
Lipid-based formulations for administration of rna
|
WO2023165681A1
(en)
|
2022-03-01 |
2023-09-07 |
BioNTech SE |
Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer
|
WO2023193892A1
(en)
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
WO2024028325A1
(en)
|
2022-08-01 |
2024-02-08 |
BioNTech SE |
Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
|
WO2024028445A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
WO2024027910A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
US11773160B1
(en)
|
2022-08-05 |
2023-10-03 |
Anaveon AG |
Immune-stimulating IL-2 fusion proteins
|